Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel.
BACKGROUND
In the United States, the annual incidence of myocarditis is estimated at 1 to 10 per 100,000 population. As many as 1% to 5% of patients with acute viral infections involve the myocardium. Although many viruses have been reported to cause myopericarditis, it has been a rare or unrecognized event after vaccination with the currently used strain of vaccinia virus (New York City Board of Health).


OBJECTIVE
To describe a series of probable cases of myopericarditis following smallpox vaccination among US military service members reported since the reintroduction of vaccinia vaccine.


METHODS
Surveillance case definitions are presented. The cases were identified either through sentinel reporting to US military headquarters surveillance using the Defense Medical Surveillance System or reports to the Vaccine Adverse Event Reporting System using International Classification of Diseases, Ninth Revision. The cases occurred among individuals vaccinated from mid-December 2002 to March 14, 2003.


METHODS
Elevated serum levels of creatine kinase (MB isoenzyme), troponin I, and troponin T, usually in the presence of ST-segment elevation on electrocardiogram and wall motion abnormalities on echocardiogram.


RESULTS
Among 230,734 primary vaccinees, 18 cases of probable myopericarditis after smallpox vaccination were reported (an incidence of 7.8 per 100,000 over 30 days). No cases of myopericarditis following smallpox vaccination were reported among 95,622 vaccinees who were previously vaccinated. All cases were white men aged 21 years to 33 years (mean age, 26.5 years), who presented with acute myopericarditis 7 to 19 days following vaccination. A causal relationship is supported by the close temporal clustering (7-19 days; mean, 10.5 days following vaccination), wide geographic and temporal distribution, occurrence in only primary vaccinees, and lack of evidence for alternative etiologies or other diseases associated with myopericarditis. Additional supporting evidence is the observation that the observed rate of myopericarditis among primary vaccinees is 3.6-fold (95% confidence interval, 3.33-4.11) higher than the expected rate among personnel who were not vaccinated. The background incidence of myopericarditis did not show statistical significance when stratified by age (20-34 years: 2.18 expected cases per 100,000; 95% confidence interval [CI], 1.90-2.34), race (whites: 1.82 per 100,000; 95% CI, 1.50-2.01), and sex (males: 2.28 per 100,000; 95% CI, 2.04-2.54).


CONCLUSIONS
Among US military personnel vaccinated against smallpox, myopericarditis occurred at a rate of 1 per 12 819 primary vaccinees. Myopericarditis should be considered an expected adverse event associated with smallpox vaccination. Clinicians should consider myopericarditis in the differential diagnosis of patients presenting with chest pain 4 to 30 days following smallpox vaccination and be aware of the implications as well as the need to report this potential adverse advent.
Halsell
Jeffrey S
JS
The University of Virginia, Charlottesville, USA.
Riddle
James R
JR
Atwood
J Edwin
JE
Gardner
Pierce
P
Shope
Robert
R
Poland
Gregory A
GA
Gray
Gregory C
GC
Ostroff
Stephen
S
Eckart
Robert E
RE
Hospenthal
Duane R
DR
Gibson
Roger L
RL
Grabenstein
John D
JD
Arness
Mark K
MK
Tornberg
David N
DN
D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D000787:Angina Pectoris / Q000175:diagnosis; D001706:Biopsy; D003937:Diagnosis, Differential; D006801:Humans; D017589:Immunization Programs; D008297:Male; D008889:Military Personnel; D009205:Myocarditis / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000821:virology; D010493:Pericarditis / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000821:virology; D012900:Smallpox Vaccine / Q000009:adverse effects*; D014481:United States / Q000453:epidemiology; D014611:Vaccination / Q000009:adverse effects* / Q000706:statistics & numerical data; D014616:Vaccinia virus / Q000302:isolation & purification
D012900:Smallpox Vaccine